Health AI Central
Share:
Peer-Reviewed Publication
Front Oncol2025;151577468.January 1, 2025Journal Article

Clinical outcomes of DNA-damaging agents and DNA damage response inhibitors combinations in cancer: a data-driven review.

Rick Fontenot1, Neha Biyani1, Kishor Bhatia1, Reggie Ewesuedo1, Marc Chamberlain1,2, Panna Sharma1,2
1Lantern Pharma Inc., Dallas, TX, United States.
2Starlight Therapeutics, Plano, TX, United States.
PubMed PMC DOI PDF

Abstract

The combination of DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis) has been extensively studied to improve therapeutic outcomes. While both groups of agents show promise individually, DDAs are limited by tumor resistance, and DDRis are limited by specific genetic context. Combining DDAs with DDRis may overcome these challenges and enhance patient outcomes. This review systema…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.